Abstract |
The incidence of mycotic infections is on the rise in the United States. The failure of patients and clinicians to recognize a fungal infection early may lead to extensive, severe, and difficult-to-treat disease. Treatment decisions must include an awareness of the etiologic organism involved, the potential for long-term recurrence, symptoms such as inflammation and itching, and the importance of patient adherence to treatment. Sertaconazole nitrate, a broad-spectrum imidazole agent with antifungal, antibacterial, antiinflammatory, and antipruritic properties, is the topical antifungal agent most recently approved by the US Food and Drug Administration. A review of its mechanisms of action, pharmacokinetic profile, fungistatic and fungicidal activities, and clinical properties examines a substantial body of research findings that establish its efficacy, safety, and tolerability. Its use in the treatment of tinea pedis and other superficial mycotic infections is reviewed here.
|
Authors | James Q Del Rosso |
Journal | Cutis
(Cutis)
Vol. 81
Issue 6 Suppl
Pg. 4-18; quiz 19-20
(Jun 2008)
ISSN: 0011-4162 [Print] United States |
PMID | 18693645
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antifungal Agents
- Imidazoles
- Thiophenes
- sertaconazole
|
Topics |
- Antifungal Agents
(therapeutic use)
- Dermatomycoses
(drug therapy)
- Humans
- Imidazoles
(therapeutic use)
- Thiophenes
(therapeutic use)
|